The price you pay for Kadcyla may depend on several factors. These include your dosage and whether you have health insurance. Financial assistance may be available to help with Kadcyla’s cost.

NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.

As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla. The Swiss pharma firm has announced that ...